Answers are grounded in this paper and cite their sources.
Innovations in cancer immunotherapy over the past decade have reinvigorated the field, which currently stands poised to transform treatment of certain important cancer types. While recent discoveries in immunotherapy have occurred in an era of intense focus on precision medicine-spurred in large part by advances in sequencing technologies allowing for unprecedented insights into individual and tumor genomes-the field of cancer immunotherapy is rooted in a history that is anything but precise. The idea that the immune system could be used to target cancer has existed for over a century. In the 1890s, William Coley provided a spark by noting a connection between spontaneous tumor regressions and concurrent bacterial infections Suspecting an immune mechanism, Coley and many others in the decades that followed experimented with live bacteria, toxins, vaccines, and countless other agents to coax the immune system to attack cancer, yielding only a tiny number of positive responses and little understanding of the underlying immune mechanisms. As recently as 2010, immunotherapy remained a strikingly imprecise endeavor, with the only United States Food and Drug Administration (FDA)-approved cancer immunotherapies being a pair of systemic cytokines-interferon- and interleukin-2-and intravesical bacillus Calmette-Gue rin (BCG). However, as recent successes reshape the field, efforts to comprehend and harness precise mechanisms in immunotherapy will be required.
No takes yet. Share an insight, caveat, or question.
Su et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: